Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site~2. any stage (Ann Arbor I-IV)~3. either de novo, or relapsed disease following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma)~4. no evidence of histologic transformation to a high grade lymphoma~5. measurable or evaluable disease~6. age \> 18~7. life expectancy of at least 1 year~8. ECOG performance status 0-2~9. no prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer~10. no prior chemotherapy~11. no prior immunotherapy with any anti-CD20 monoclonal antibody~12. no prior radiotherapy in the last 6 weeks~13. no corticosteroids during the last 28 days, unless prednisone chronically administered at a dose \<20 mg/day for indications other than lymphoma or lymphoma-related symptoms~14. no evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry~15. no evidence of symptomatic central nervous system (CNS) disease~16. no impairment of bone marrow function (WBC \>3.0x109/L, ANC \>1.5x109/L, PLT \>100x109/L), unless due to lymphoma involvement~17. no major impairment of renal function (serum creatinine \<1,5x upper normal) or liver function (ASAT/ALAT \<2,5 upper normal, total bilirubin \<2,5x upper normal), unless due to lymphoma involvement~18. no evidence of active opportunistic infections~19. no known HIV infection~20. no active HBV and/or HCV infection~21. no pregnant or lactating status~22. appropriate contraceptive method in women of childbearing potential or men~23. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~24. informed consent must be given according to national/local regulations before randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: ACTIVE_COMPARATOR): chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment; two weeks rest; chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
- ARM B (Type: EXPERIMENTAL): rituximab 375 mg/m2 iv, d1, d8, d15, d22 chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment two weeks rest chlorambucil 6 mg/m2 os daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
- ARM C (Since April 2006) (Type: EXPERIMENTAL): rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete